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377HIGHLIGHTS
 Combining CHD phenotype–driven gene set enrichment and CRISPR knockdown screening in zebrafish is
an effective approach to identifying novel CHD genes.
 Mutations affecting genes coding for the WAVE2 protein complex and small GTPase-mediated signaling
are associated with LVOTO lesions.
 WAVE2 complex genes brk1, nckap1, and wasf2 and regulators of small GTPase signaling cul3a and racgap1
are critical to zebrafish heart development.
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MaGenetic variants are the primary driver of congenital heart disease (CHD) pathogenesis. However, our ability to
identify causative variants is limited. To identify causal CHD genes that are associated with specific molecular
functions, the study used prior knowledge to filter de novo variants from 2,881 probands with sporadic severe
CHD. This approach enabled the authors to identify an association between left ventricular outflow tract
obstruction lesions and genes associated with the WAVE2 complex and regulation of small GTPase-mediated
signal transduction. Using CRISPR zebrafish knockdowns, the study confirmed that WAVE2 complex proteins
brk1, nckap1, and wasf2 and the regulators of small GTPase signaling cul3a and racgap1 are critical to cardiac
development. (J Am Coll Cardiol Basic Trans Science 2020;5:376–86) © 2020 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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378C ongenital heart disease (CHD) is the mostcommon clinically devastating birth defect(1). Among the multiple factors that drive
CHD pathogenesis, genetic variants appear to be a
primary driver (2,3). Despite greater understanding
of the molecular mechanisms of heart development,
our ability to definitively identify specific genetic
causes for most patients has progressed more slowly.
A barrier to unraveling genotype-phenotype asso-
ciations is the high degree of genetic heterogeneity,
such that analysis of even a moderate-sized cohort
results in a relatively low number of genes observed
to be mutated recurrently (4,5). Hence, identifying
novel CHD genes is well suited for network analysis,
wherein discrete mutations and affected genes can be
connected based on prior knowledge of gene-gene
functional networks such as associations with devel-
opmental pathways and known protein-protein
interactions. Together, these functional data can
provide a platform to identify molecular pathways
that link variants to prioritize identification and lead
to the discovery of novel candidate causal CHD genes.
Validation of selected genes in model systems will
ultimately expand our ability to detect genetic
etiologies for patients.
Initial whole exome sequencing from the Pediatric
Cardiac Genomics Consortium (PCGC) identified a
burden of de novo exonic mutations in genes with
higher fetal heart expression (HHE) in sporadic,
severe CHD accounting for 10% of cases (4). Gene
Ontology enrichment analyses identified altered
epigenetic regulators, particularly histone modifiers,
as important for CHD pathogenesis. Subsequent PCGC
whole exome sequencing studies have identified a
significant overlap between HHE and high fetal brain
expression for mutated genes identified in CHD pro-
bands—thus providing a potential mechanism for the
frequent co-occurrence of extracardiac anomalies or
neurodevelopmental delays (6). More recently, whole
exome sequencing of this growing cohort of sporadic,
severe CHD characterized the contribution of reces-
sive variants in genes well established to cause
CHD in human and mouse studies (7). To expand on
these, we performed unbiased global analyses of
phenotype-specific CHD-associated variants to prior-
itize candidate causal genes and identify pathways
relevant for CHD pathogenesis.
METHODS
EXOME SEQUENCING AND VARIANT FILTERING.
Whole exome sequencing results from 2,881 sporadic,
severe CHD trios enrolled in the PCGC or Pediatric
Heart Network were compared with whole exomesequencing from 900 control trios in Simon’s Foun-
dation Autism Research Initiative Simplex Collection
(6). The research protocols were approved by the
Institutional Review Boards at each participating
center—Boston’s Children’s Hospital, Brigham and
Women’s Hospital, Great Ormond Street Hospital,
Children’s Hospital of Los Angeles, Children’s Hos-
pital of Philadelphia, Columbia University Irving
Medical Center, Icahn School of Medicine at Mount
Sinai, Rochester School of Medicine and Dentistry,
Steven and Alexandra Cohen Children’s Medical
Center of New York, and Yale School of Medicine.
Briefly, sequencing for case and control trios was
performed at Yale Center for Genome Analysis using
NimbleGen v2.0 exome capture reagent (Roche,
Basel, Switzerland) and Illumina HiSeq 2000, 75-bp
paired-end reads (Illumina, San Diego, California).
Three independent analysis pipelines were used to
process reads and were mapped to hg19 using
Novoalign (Novocraft Technologies, Selangor,
Malaysia) and Genome Analysis Toolkit 3.0 (Broad
Institute, Cambridge, Massachusetts) best practices at
Harvard Medical School and BWA-mem at Yale School
of Medicine and Columbia University Medical Center
(8,9), Variant calls were made using GATK Hap-
lotypeCaller (8). De novo variants not meeting the
following criteria after pooling from the 3 pipelines
were filtered out: depth (minimum 10 reads total and
5 alternate allele reads), alternate allele balance
(minimum 20% if alternate read depth $10 or mini-
mum 28% if alternate read depth <10), and parental
read characteristics (minimum depth of 10 reference
reads and alternate allele balance <3.5%).
Variant pathogenicity was assessed using in silico
prediction from PredictSNP2 (Loschmidt Labora-
tories, Brno, Czech Republic), which employs an
ensemble approach by integrating data from multiple
in silico tools, for all variants other than frameshift
mutations (10). As PredictSNP2 does not score
frameshift mutations, we used Combined Annotation
Dependent Depletion v1.4 for these variants (11).
Combined Annotation Dependent Depletion, 1 of the
tools which contributes to PredictSNP2, yields
PHRED-scaled C scores, such that a score of $30
correlates to the top 0.1% of all possible variants and
in prior studies has been used to discriminate
pathogenic from tolerated frameshift variants (11).
Variants were also filtered for those affecting HHE
genes (4). The HHE gene set was previously identified
using RNA sequencing of isolated strain 129/SvEV
mouse hearts including atria, ventricles, and all 4
valves at embryonic day 14.5 to dichotomize 16,676
genes with identified human-mouse orthologues with
a minimum of 40 reads per million mapped reads into
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379the top quartile of expression (4). The HHE gene list
consists of 4,169 genes, and the low heart expression
list consists of 12,507 genes.
We considered that the low heart expression genes
may contain some genes critical to cardiogenesis, so
in an orthogonal variant filtering, we excluded genes
unlikely to have a role in cardiovascular development
based on knockout mouse phenotypes using the
Mouse Genome Informatics (MGI) knockout pheno-
type gene library (12). Specifically, a gene was
excluded if its knockout had been phenotyped, and
the knockout was not found to cause any cardiovas-
cular related phenotype, embryogenesis phenotype,
or embryonic or postnatal lethality.
Cardiac diagnoses were obtained from the PCGC
Data Hub (13). Left ventricular outflow tract obstruc-
tion (LVOTO) (n ¼ 802) included hypoplastic left heart
syndrome, aortic coarctation, and aortic stenosis.
Conotruncal defects (CTDs) (n ¼ 1120) included
D-transposition of the great arteries, tetralogy of Fal-
lot, double outlet right ventricle, truncus arteriosus,
ventricular septal defects, and abnormalities of the
aortic arch patterning. Heterotaxy (HTX) (n ¼ 274)
included patients with left-right isomerism as the
primary defect. The remaining patients not included in
1 of the 3 phenotype categories consisted of a hetero-
geneous group of defects including atrial septal de-
fects and anomalous pulmonary venous connections,
pulmonary valve lesions, atrioventricular canal de-
fects, double inlet left ventricle, and tricuspid atresia.
GENE SET ENRICHMENT ANALYSIS. We performed
gene set enrichment analysis for Gene Ontology bio-
logical processes (GOBP) terms and Comprehensive
Resource of Mammalian Protein Complexes (CORUM)
using HHE in silico– and MGI library in silico–filtered
variants and the hypergeometric test. Enrichment
analyses were performed with Enrichr (Icahn School
of Medicine at Mount Sinai, New York, New York),
which, in addition to implementing the hypergeo-
metric test, also employs a ranking method that
combines the adjusted p value with a deviation from
the expected rank based on enrichment analysis
applied to random gene sets (z-score) (14). In addi-
tion, we repeated the enrichment analysis with the
loading of 2 different background reference lists;
1 made of the 4,169 HHE genes and the other made of
the entire human genome excluding the MGI library
phenotype negative genes using WebGestalt
(Vanderbilt University Medical Center, Nashville,
Tennessee) with the default settings (15). The refer-
ence and background gene lists are available in
supplemental information. A Benjamini-Hochberg–
adjusted p < 0.05 using both tools, Enrichr andWebGestalt, was used for significance with significant
terms ranked by Enrichr’s combined score. Gene
Ontology enrichment analysis was performed for
controls, all cases, and LVOTO, CTD, and HTX
gene lists.
Given that among the CHD phenotype–specific
groups, significant enrichment was only observed
for the LVOTO group, we performed a protein-protein
interaction (PPI) network analysis only for this group
to prioritize candidate genes. We generated an
LVOTO-specific PPI network, using GeNets (Broad
Institute, Cambridge, Massachusetts), by inputting all
LVOTO genes associated with all GOBP and CORUM
terms identified as enriched including terms which
were observed as enriched when using only Enrichr
or WebGestalt enrichment analyses. Then we ranked
genes associated with the consistently enriched terms
by their number of connections identified in the
LVOTO-specific PPI network.
A flow diagram of the variant filtering and enrich-
ment analyses is provided in Supplemental Figure 1.
MODELING LOSS OF CANDIDATE GENES IN ZEBRAFISH
EMBRYOS. Clustered regularly interspaced short
palindromic repeats (CRISPR)–mediated knockdown
experiments were performed for candidate genes in
zebrafish F0 embryos to assess morphological
phenotypes, as described previously (16). Briefly,
wild-type AB strain zebrafish embryos were injected
at the 1- to 2-cell stage with zebrafish-optimized Cas9
protein and CRISPR RNAs targeting abi1, brk1, cyfip1
cul3a, nckap1, racgap1, or wasf2. CRISPR design and
construction were performed by the University of
Utah Mutation Generation and Detection Core using
standard best practice procedures. Single guide RNAs
were designed for high efficiency and low off-target
effects, and concentrations for single guide RNA and
cas9 protein were also titrated for optimal impact.
The mutagenic efficiency of each CRISPR and vali-
dation of double-stand breaks was assessed using
high-resolution melting analysis performed on
genomic DNA from individual injected embryos (17).
CRISPR target sequences and high-resolution melting
analysis primer sequences are listed in Supplemental
Table 1. Zebrafish embryos were phenotyped at 2 days
past fertilization. To evaluate cardiac morphology
and function, wild-type and mutant lines of zebrafish
were evaluated on a cmlc2-GFP background and
visualized with a fluorescent microscope.
STATISTICS. The burden of de novo mutations in
controls was compared with that found in all CHD
cases and then separately for the LVOTO, CTD, and
HTX phenotype groups. A 2-tailed chi-square analysis
was performed to generate the odds ratio with 95%
TABLE 1 Mutation Burden by Variant Filter and Phenotype
Mutation Type
Controls
(n ¼ 900) Cases (n ¼ 2,881) LVOTO (n ¼ 802) CTD (n ¼ 1,120) HTX (n ¼ 274)
Var Var
OR
(95% CI)
Adjusted
p Value Var
OR
(95% CI)
Adjusted
p Value Var OR (95% CI)
Adjusted
p Value Var OR (95% CI)
Adjusted
p Value
All 945 3010 863 1,150 247
In silico 362 1,237 1.12 (0.96–1.30) 0.145 375 1.24 (1.03–1.45) 0.051 473 1.13 (0.94–1.34) 0.273 89 0.91 (0.68–1.21) 0.560
HHE in silico 116 583 1.73 (1.39–2.13) <0.001 185 1.96 (1.51–2.51) <0.001 223 1.73 (1.35–2.19) <0.001 36 1.23 (0.81-1.83) 0.469
MGI library
in silico
178 819 1.61 (1.34–1.93) <0.001 252 1.78 (1.43–2.21) <0.001 304 1.55 (1.26–1.91) <0.001 52 1.15 (0.81–1.63) 0.531
Odds ratios (ORs) calculated comparing filter-selected with filtered-out variants between controls and cases or phenotype groups. All p values adjusted using Benjamini-Hochberg p < 0.05 for significance.
CI ¼ confidence interval; CTD ¼ conotruncal defect; HHE ¼ high fetal heart expression; HTX ¼ heterotaxy; MGI ¼ Mouse Genome Informatics; Var ¼ variants.
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380confidence interval comparing the number of filter-
selected variants (in silico, HHE in silico, or MGI
library in silico) to filtered-out variants for each group
comparedwith controls. As described previously, gene
set enrichment was assessed using a hypergeometric
test. All reported p values were adjusted using the
Benjamini-Hochberg method. A p value <0.05 was
considered statistically significant and R software
version 3.5.2 (R Foundation for Statistical Computing,
Vienna, Austria) was used for all statistical analyses.
DATA AVAILABILITY. Whole exome sequencing
data have been previously deposited in the data-
base of Genotypes and Phenotypes (dbGaP) under
accession number phs000571.v1.p1, phs000571.v2.p1,
and phs000571.v3.p2.
RESULTS
EXOMESEQUENCINGANDVARIANTFILTERING. Consistent
with the initial PCGC cohort and as published for this
expanded PCGC cohort, the rate for all de novo vari-
ants in patients with CHD was not significantly
different from healthy controls (1.04 vs. 1.05 variants/
individual) (4,6,7). This was also true for the LVOTO
(n ¼ 802), CTD (n ¼ 1120), and HTX (n ¼ 274) groups
(1.08, 1.03, and 0.90 de novo variants per individual,
respectively). Variant pathogenicity was assessed us-
ing in silico prediction from PredictSNP2 and Com-
bined Annotation Dependent Depletion (10,11). With
the exception of HTX, which did not demonstrate
significant burden with any combination of filters, all
cases, LVOTOs, and CTDs exhibited increasing burden
with each layer of filtering (Table 1). The HHE in silico
filter demonstrated the greatest burden, with odds
ratios of 1.7, 2.0, and 1.7 (p < 0.001, for all) for all cases,
LVOTOs, and CTDs, respectively, with comparable
burden identified using the MGI library in silico.
GENE SET ENRICHMENT ANALYSES. We performed
GOBP and CORUM gene set enrichment analyses
using the hypergeometric test with the MGI library insilico– and HHE in silico–filtered gene lists derived
from all cases, CHD phenotypes, and control groups.
Hypergeometric tests were performed using Enrichr
and WebGestalt as described in the Methods (14,15).
Using the MGI library in silico–filtered gene set from
all cases, we identified 181 GOBP and 4 CORUM
enriched terms. Similarly, using WebGestalt, we
identified 140 GOBP and 3 CORUM enriched terms, of
which 17 common GOBP and 2 common CORUM terms
identified as significant with both tools (Supplemental
Table 2). The relatively low overlap in enriched terms
between Enrichr and WebGestalt is likely due to
different methods to convert the Gene Ontology tree
into a gene set library and different versions of the
Gene Ontology tree. Notable enriched terms included
the following developmental pathways and processes:
heart morphogenesis, vasculogenesis, VEGF receptor
signaling, beta-catenin-TCF complex, and regulation
of actin filament–based processes. Using the same
approach for the LVOTO phenotype genes, we identi-
fied enrichment for 23 GOBP and 3 CORUM enriched
terms using Enrichr and 39 GOBP and 2 CORUM
enriched terms using WebGestalt, with 2 from each li-
brary consistently enriched using both tools: regula-
tion of actin filament-based processes, VEGF receptor
signaling, WAVE2 complex, and ITGA6-ITGB4-
Laminin 10/12 complex (Table 2).
Similar themes emerged from enrichment results
using HHE in silico–filtered gene sets for all cases and
LVOTO groups but with overall narrower overlapping
results. From all cases, 4 GOBP and 1 CORUM term
were consistently identified as enriched: heart
morphogenesis, ephrin receptor signaling, regulation
of small GTPase-mediated signal transduction, acto-
myosin structure organization, and BAF complex
(Supplemental Table 3). For LVOTO, the highest-
ranked CORUM protein complex identified by
Enrichr was WAVE2. One GOBP term was consistently
enriched using both tools: regulation of small
GTPase-mediated signal transduction (Table 2).
TABLE 2 LVOTO Gene Set Enrichment
Gene List Library Term Combined* Fold†
Adjusted
p Value† Genes
MGI library in silico CORUM Wave-2 complex 1709.0 32.6 0.011 ABI1;CYFIP1;NCKAP1
MGI library in silico CORUM ITGA6-ITGB4-Laminin10/12 complex 692.9 32.6 0.011 LAMA5;LAMB1;LAMC1
MGI library in silico GOBP Regulation of actin filament–based process 77.1 3.5 0.003 ABL2;DLC1;TENM1;ASAP3;
SPTA1;SSH2;ANK2;TSC1;SMAD4;
CYFIP1;NCKAP1;LRP1;RAC1;
CDC42;RYR2;MTOR;ROCK1
HHE in silico GOBP Regulation of small GTPase-mediated
signal transduction
73.6 3.8 0.002 FOXM1;NF1;NOTCH2;NOTCH1;
ARAP3;DLC1;CUL3;SIPA1L1;
ITSN2;KALRN;TNFAIP1;RHOT2;
RACGAP1;RAF1;RAC1;CDC42
MGI library in silico GOBP Vascular endothelial growth factor
receptor signaling pathway
63.5 5.3 0.017 MYOF;ABI1;CYFIP1;NCKAP1;
RAC1;CDC42;ROCK1
Gene set enrichment was performed using HHE and MGI library in silico–filtered genes with the hypergeometric overrepresentation test implemented using Enrichr and
WebGestalt. Terms were filtered for statistical significance if Benjamini-Hochberg–adjusted p < 0.05 using both tools. *Combined score derived from Enrichr, which is a unique
ranking system that combines the adjusted p value with a deviation from expected ranking for each term based on inputting random gene sets. †Fold enrichment and adjusted
p values presented from WebGestalt using background gene list correction.
CORUM ¼ Comprehensive Resource of Mammalian Protein Complexes; GOBP ¼ Gene Ontology biological processes; other abbreviations as in Table 1.
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381Much less enrichment was observed for the CTD,
HTX, and control gene lists, with no terms reaching
statistical significance for the control or the HTX MGI
library in silico or HHE in silico gene lists using either
tool. For CTDs, only 1 GOBP term—pericardium
development—was consistently enriched using the
MGI library in silico–filtered genes. No term
was consistently enriched using HHE in silico–
filtered CTD genes. Complete results of patient phe-
notypes and variants and complete enrichment
analyses results are included in the Supplemental
Appendix.
Across all enrichment analyses, LVOTO-driven
WAVE2 complex enrichment demonstrated the high-
est Enrichr combined score and WebGestalt fold
enrichment. Variants affecting 3 of the 5 genes
encoding proteins within the WAVE2 complex and
the direct regulator of WAVE2 (RAC1) were identified
in LVOTO probands with none identified in other
phenotypes: nonsense variants in ABI1 (p. R106X) and
NCKAP1 (p. E1057X) and damaging missense variants
in CYFIP1 (p. S35L) and RAC1 (p. R68C). PredictSNP2
scores ranged from 0.69 to 1.0 (maximum) and C
scores were $32 (0.06% most damaging variants) for
these 4 variants. The WAVE2 complex functions
downstream of the small GTPase RAC1 to regulate
branched actin synthesis and influence actin cyto-
skeleton organization in multiple cellular processes,
including cell migration through formation of lamel-
lipodia (18,19). In this context, it is notable that in
addition to consistent enrichment observed for actin
filament–based processes and regulation of small
GTPase signaling, terms related to lamellipodium and
actin cytoskeleton development were identified as
enriched in at least 1 context.We considered that visualizing protein network
interactions between genes associated with the
LVOTO enriched terms would allow us to better pri-
oritize candidate genes for downstream validation. To
that end, we used Metanetwork v1.0 (Broad Institute)
predicted protein-protein interactions available from
GeNets to interrogate for interactions between the 35
genes associated with the 5 consistently enriched
GOBP and CORUM terms and all genes associated with
all LVOTO enriched terms (Figure 1) (20). These 35
genes had a median of 3 connections in this LVOTO-
specific protein network with CUL3, CDC42, CYFIP1,
NCKAP1, NF1, NOTCH1, RAC1, RACGAP1, and RAF1
being in the top quartile with 7 to 14 connections each.
Unsurprisingly, most of these genes are already
strongly implicated in cardiac development and CHD
(21–25). Notably, both Cul3–/– and Racgap1–/– result in
embryonic lethality, suggesting a possible role in heart
development, which is further supported by a more
recent cardiomyocyte-specific Cul3–/– demonstrating a
developmental cardiomyopathy and postnatal
lethality (26–28).
The role of the WAVE2 complex, which consists of
the 3 previously mentioned genes as well as BRICK1
and WASF2, in cardiogenesis is mostly unknown.
Mouse knockout studies of Abi1, Brick1, and Cyfip1
resulted in embryonic lethality, with the only
reported cardiac phenotype being hemorrhagic peri-
cardial edema or discontinuous cardiac tissue layers
from loss of Abi1 (29–32). Additionally, loss of Wasf2
resulted in reversed cardiac looping in 1 of 2 mouse
models and loss of Nckap1 resulted in cardia bifida in
mice (33–35). Therefore, we selected the 5 WAVE2
complex genes, cul3a, and racgap1 for further
validation in zebrafish embryos.
FIGURE 1 LVOTO Disease Gene Network
Bipartite graph generated using GeNets Metanetwork v1.0 protein-protein interactions connecting left ventricular outflow tract obstruction (LVOTO) genes associated with
enriched terms using either high fetal heart expression (HHE) in silico or Mouse Genome Informatics (MGI) library in silico–filtered genes and either Enrichr or WebGestalt.
Of the genes associated with consistently enriched terms and not previously implicated in structural heart defects, CUL3 and RACGAP1 are the most strongly connected.
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382MODELING LOSS OF CANDIDATE GENES IN ZEBRAFISH
EMBRYOS. Zebrafish was selected for gene knock-
down as its ability to survive via oxygen diffusion in
the absence of a functional cardiovascular system
permits the study of lethal cardiac defects later in
development (36). Using CRISPR-guided knockdown,we observed cardiac phenotypes in F0 embryos with
mosaic loss of brk1, cul3a, nckap1, racgap1, and wasf2
(Table 3). Reversed cardiac looping was observed in
brk1, cul3a, nckap1, and wasf2 knockdown embryos,
while racgap1 knockdown resulted in zebrafish em-
bryos with a small, poorly contractile ventricle often
TABLE 3 Phenotypes of CRISPR Gene Knockdown F0 Zebrafish
Target
Gene
Reversed Heart
Looping Atrial and Ventricular Size Circulation
Head/Brain/Eye
Structures
cul3a 8/64 (13) Normal Normal Normal
wasf2 19/102 (19) Normal Normal Normal
racgap1 6/105 (6) Dilated atria and small
ventricle 42/105 (42)
Normal Hypoplastic
99/105 (95)
brk1 23/122 (19) Normal Normal Normal
nckap1 16/83 (19) Normal Normal Normal
cyfpl1 1/75 (1.3) Normal Normal Normal
abi1 1/72 (1.4) Normal Normal Normal
Values are n/N (%). Most (5 of 7) candidate genes demonstrate abnormal cardiac development in
CRISPR-mediated knockdown, including reversed cardiac looping in 3 WAVE2 complex genes
(brk1, nckap1, and wasf2) and cul3a. Loss of racgap1 also demonstrated extracardiac anomalies in
addition to a small ventricle and atrial dilation.
CRISPR ¼ clustered regularly interspaced short palindromic repeats.
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383with associated atrial dilation (Figure 2). Notably, all 7
of these genes are both highly expressed in the
developing heart and brain of the mouse, but a brain
phenotype was only observed in racgap1 knockdown
embryos (6).
DISCUSSION
HUMAN GENETICS. In this study, we used whole
exome sequencing of 2,881 well-phenotyped, spo-
radic CHD trios and compared these with 900 control
trios to identify de novo predicted damaging muta-
tions using in silico, developmental heart expression,
and previous implications in development or cardiac
disease in knockout mouse phenotypes. As gene set
enrichment analyses are sensitive to both the length
of the genes list associated with each term and the
background gene list, we performed enrichment
analysis with different methods and considered not
only statistical significance, but also consistency
across tools and algorithms.
Through phenotype-driven elaborate gene set
enrichment analyses, we identified a novelFIGURE 2 Crispr-Mediated Candidate Gene Knockdown in Zebrafish
(A, C) Wild-type (WT), (C) cul3a, and (D) racgap1 knockout (KO) zebrafis
cul3a KO as compared with WT, both on a cmlc2-GFP background. The
edema. At ¼ atria; CRISPR ¼ clustered regularly interspaced short palinassociation between the LVOTO phenotype and genes
associated with the WAVE2 complex, actin-filament
based processes, and small GTPase signal trans-
duction. The WAVE2 complex comprises 5 proteins
(gene symbols in parentheses when different)—
WAVE2 (WASF2), HSPC300 (BRK1), CYFIP1, NCKAP1,h at 2 days past fertilization. Reversed cardiac looping illustrated in
racgap1 KO zebrafish demonstrate atrial dilation and pericardial
dromic repeats; Ve ¼ ventricle.
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384and ABI1—and is regulated by the small GTPase RAC1
to mediate branched actin synthesis, a key contrib-
utor to actin cytoskeleton organization, via Arp2/3-
mediated actin polymerization (18). Enrichment an-
alyses also identified CUL3 and RACGAP1 as media-
tors of small GTPase signaling. Placing the protein
products of these genes within a PPI network we
further highlight their strong connections within an
LVOTO-specific network.
In contrast to LVOTO, the other phenotype groups
demonstrated significantly less term enrichment.
Although CTDs had similar variant burden to LVOTO,
we hypothesize that genetic and phenotypic hetero-
geneity within this group may have limited our ability
to identify consistent term enrichment with our
approach. For HTX, we failed to identify a burden of
mutations or identify any significant term enrichment
using any combination of enrichment tools or gene
filter. The smaller size of the HTX cohort compared
with the other phenotypes may have limited our
power for enrichment analysis, but limiting to de novo
variants may also have missed significant genetic
contributors. Recent results from the PCGC highlight
that recessively inherited variants contribute
substantially to pathogenesis of patients with CHD and
laterality defects, suggesting that this model of in-
heritance needs to be incorporated into all future gene
pathway enrichment studies for patients with HTX (7).
CANDIDATE GENE VALIDATION IN ZEBRAFISH. Given
consistency of LVOTO gene set enrichment, we
selected candidate genes from this group for valida-
tion. We identified reversed cardiac looping with loss
of brk1, cul3a, nckap1, and wasf2 and a small ventricle
with atrial dilation and pericardial edema with loss of
racgap1 in F0 zebrafish embryos. It is difficult to
directly compare reversed cardiac looping in zebra-
fish with LVOTO defects in humans. Being comprised
of only 2 chambers renders the developing zebrafish
heart vulnerable to looping defects from mechanisms
other than perturbed sidedness including altered
myocardial cell polarity, cell number, or blood flow
(37). Thus, while these results in zebrafish cannot
definitively implicate these genes in LVOTO, we can
conclude their critical nature to cardiac development
and establish an association with mutations in these
genes and LVOTO in humans.
PROPOSED MOLECULAR MECHANISMS. Recently,
the Lo lab has developed a mouse forward genetics
screen coupled with fetal imaging and whole exome
sequencing of founder mice exhibiting a cardiovas-
cular malformation to identify recessively inherited
variants in novel CHD genes (38). This model has
illustrated a role for complex genetic inheritance inmultiple CHD phenotypes including the severest form
of LVOTO, hypoplastic left heart syndrome, in the
Ohia mouse line (Sap130m/m/Pcdha9m/m) (39). These
genes were further validated in LVOTO pathogenesis
after identifying mutations affecting SAP130 and a
related gene, PCDHA13, in patients with hypoplastic
left heart syndrome. Kyoto Encyclopedia of Genes
and Genomes network analysis of differentially
expressed genes in the Ohia right and left ventricular
tissue by RNA sequencing and chromatin immuno-
precipitation sequencing implicated multiple devel-
opmental pathways including Notch, Wnt, Tgfb, and
hedgehog signaling, as well as biological processes
including extracellular matrix receptors, regulation of
actin cytoskeleton, axon guidance, and metabolism.
WAVE2 is a highly conserved regulator of actin cyto-
skeleton and cell morphology during development, a
process that is critical to regulating cell polarity, cell
migration, cytokinesis, and tissue architecture
(35,40,41). Interestingly, the noncanonical Wnt
planar cell polarity pathway, which regulates cell
polarity during development via small RhoGTPase
regulation including RAC1, was identified as enriched
using Enrichr with both MGI library in silico– and HHE
in silico–filtered LVOTO gene lists and could provide a
mechanistic link between altered WAVE2 complex
activity and CHD (42).
Knockout studies in mouse and zebrafish demon-
strate that planar cell polarity genes influence heart
development by regulating directional migration of
progenitor cells, septation of the primitive heart
tube, and patterning of cardiac structures (43). In
loss of Wnt5a and mutants of Vangl2 and Dvl2 (which
connect planar cell polarity to RhoGTPase signaling),
abnormal outflow tract development, reduced
cardiomyocyte polarity, and actin polymerization
defects in cardiac progenitor cells are observed (44).
The direct link between planar cell polarity and
WAVE2 complex signaling is the RhoGTPase RAC1.
Early lethality has prohibited studying global loss of
Rac1, but second heart field-specific knockdown of
Rac1 resulted in abnormal right ventricular
cardiomyocyte polarity with inhibited second heart
field progenitor cell migration and concomitant
decreased expression of WAVE2 complex genes and
Arp2/3 in embryonic right ventricular tissue (22).
Taken together, these studies illustrate how
altered signaling via planar cell polarity/Rac1/
WAVE2 can disrupt normal mammalian heart
development.
In addition to contributing to small GTPase-
mediated signaling, loss of CUL3 may also
contribute to CHD through its role in ubiquitination
(45). In HEK293 cells, SAP130, a regulator of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Genetic variants
including single gene mutations or larger genomic changes, such
as copy number variations or aneuploidy, contribute substantially
to CHD pathogenesis. With the decreasing cost of next-
generation sequencing, there is more widespread genetic testing,
yet an unequivocal genetic cause is not identified in up to 80% of
CHD patients. Closing this gap in our fund of knowledge has
significant implications on genetic counseling for our patients
and their families.
TRANSLATIONAL OUTLOOK: Predicted damaging mutations
affecting genes in the WAVE2 complex and related genes are
probably causative of CHD and, more specifically, LVOTO.
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385ubiquitination via cullin-RING ligases and 1 of 2 pro-
teins implicated in the mouse Ohia line, binds CUL3
with higher affinity than other CUL proteins (46).
Additionally, Lztr1 knockout in the mouse and loss of
function LZTR1 mutations in humans have been
implicated in Noonan syndrome through decreased
CUL3-mediated RAS ubiquitination and ultimately
increased RAS/MAPK signaling (47,48). Further, in
the LVOTO-specific protein network generated in
this study, the canonical ubiquitination regulator
UBC demonstrated the highest number of
connections including with CUL3. Thus, the mecha-
nism of CUL3 loss leading to developmental cardiac
defects might also be related to dysregulated
ubiquitination.
Finally, loss of cyfip1 and abi1a, unlike the other
WAVE2 complex genes, was not found to impact
zebrafish heart development. Zebrafish, unlike mouse
or human, have 2 orthologs for ABI1 (abi1a and abi1b)
with abi1b likely compensating to maintain normal
cardiac development. Similarly, loss of cyfip1 may be
compensated by irsp53, which in mice has been
shown to also facilitate binding of activated Rac1 to
WAVE2 (49).
CONCLUSIONS
Despite rigorous efforts to unravel the genetic
mechanisms for severe forms of LVOTO pathogen-
esis, the etiology for most patients has largely
remained elusive with only recent evidence con-
firming a role for SAP130 and PCDHA13 (39). Here, we
exploited the strength of gene pathway enrichment
analyses from whole exome sequencing results of
sporadic, complex CHD trios to identify an associa-
tion with LVOTO in humans and WAVE2 complex,actin-filament regulation, and small GTPase signaling
genes. Furthermore, we confirmed a role for brk1,
cul3a, nckap1, racgap1, and wasf2 in cardiac devel-
opment using CRISPR mediated knockdown in
zebrafish. Ultimately, we illustrate that combining
phenotype-driven gene set enrichment analyses with
validation in zebrafish is as an effective approach for
identifying novel CHD genes. Given evidence linking
planar cell polarity pathway to WAVE2 complex ac-
tivity via small GTPase signaling, we propose this as a
promising framework for future mechanistic investi-
gation into LVOTO.
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